肾素-血管紧张素-醛固酮系统与心律失常关系的研究进展

摘要/Abstract

摘要： 肾素-血管紧张素-醛固酮系统（Renin-Angiotensin- Aldosterone System， RAAS）是人体内一个重要的内分泌/旁分泌系统，参与如高血压、心肌肥厚、动脉粥样硬化等多种心血管疾病的病理过程。大量数据表明，RAAS也参与心律失常的疾病过程，可引起心房颤动、室性心动过速、心室颤动等快速型心律失常的发生。目前已知，RAAS主要通过增加心肌肥厚、纤维化和心肌组织的异质性导致上述心律失常的发生。最新研究发现，RAAS还通过多种电生理效应参与心律失常的发生，血管紧张素转换酶抑制剂（angiotensin converting enzyme inhibitors，ACEIs）、血管紧张素受体拮抗剂（angiotensin receptor blockers，ARBs）和醛固酮受体阻滞剂（mineralocorticoid receptor blockers，MRBs）可减少这些心律失常的发生。本文重点探讨RAAS在心律失常发生中的作用及可能的分子机制，为临床预防以及治疗以上心律失常提供新的方向。

关键词: font-size:medium, ">肾素-血管紧张素-醛固酮系统；心律失常；预防；治疗

Abstract: The Renin-Angiotensin-Aldosterone System（RAAS) is an important endocrine/paracrine system in the human body， which is involved in the pathophysiological processes of various cardiovascular diseases， such as hypertension， cardiac hypertrophy， and atherosclerosis. A large number of datas show that RAAS is also involved in the disease process of arrhythmia， which can cause the occurrence of tachyarrhythmias， such as atrial fibrillation， ventricular tachycardia and ventricular fibrillation. It is currently known that RAAS leads to tachyarrhythmias mainly by the ways of cardiac hypertrophy， fibrosis and heterogeneity of myocardial tissue. The latest study has found RAAS having multiple electrophysiological effects involved in the arrhythmia occurrence. Angiotensin-converting enzyme inhibitors (ACEIs)， angiotensin receptor antagonists (ARBs) and aldosterone receptor blockers (MRBs) can reduce the occurrence of tachyarrhythmias. We will summarize the role and possible molecular mechanism of RAAS in tachyarrhythmia， and provide a new direction for the clinical prevention and treatment of the above arrhythmia.

Key words: font-size:medium, ">Renin-angiotensin-aldosterone System； Arrhythmias； Prevent；Therapy

中图分类号:

崔明丽, 杨寿娟, 徐会圃, 刘振, 张贝. 肾素-血管紧张素-醛固酮系统与心律失常关系的研究进展[J]. 中国医药导刊, 2023, 25(2): 151-155.

CUI Mingli, YANG Shoujuan, XU Huipu, LIU Zhen, ZHANG Bei. Relationship Between Renin-Angiotensin-Aldosterone System and Arrhythmias[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(2): 151-155.

参考文献

[1]Schmieder RE， Hilgers KF， Schlaich MP， et al. Renin-angiotensin system and cardiovascular risk[J].Lancet， 2007，369：1208-1219.
     [2]Carey RM， Siragy HM. Newly recognized components of the renin-angiotensin system： potential roles in cardiovascular and renal regulation[J]. Endocr Rev， 2003，24：261-271.
     [3]Trask AJ， Ferrario CM. Angiotensin-(1-7)： Pharmacology and new perspectives in cardiovascular treatments[J]. Cardiovasc Drug Rev， 2007，25：162-174.
     [4]Pitt B， Remme W， Zannad F， et al. Eplerenone， a selective aldosterone blocker， in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med， 2003，348：1309-1321.
     [5]Pitt B， Zannad F， Remme WJ， et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med，1999，341：709-717.
     [6]Sepehrdad R， Frishman WH， Stier CT Jr， et al. Direct inhibition of renin as a cardiovascular pharmacotherapy： Focus on aliskiren[J]. Cardiol Rev， 2007，15：242-256.
     [7]Madrid AH， Bueno MG， Rebollo JM， et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation： A prospective and randomized study[J]. Circulation，2002，106：331-336.
     [8]Ueng KC， Tsai TP， Yu WC， et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study[J]. Eur Heart J， 2003，24：2090-2098.
     [9]Zaman AG， Kearney MT， Schecter C， et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation[J]. Am Heart J， 2004，147：823-827.
     [10]Vermes E， Tardif JC， Bourassa MG， et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction： Insight from the studies of left ventricular dysfunction(SOLVD) trials[J]. Circulation， 2003，107：2926-2931.
     [11]Wachtell K， Lehto M， Gerdts E， et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol： the losartan intervention for end point reduction in hypertension (LIFE) study[J]. J Am Coll Cardio，l 2005，45：712-719.
     [12]Murray KT， Rottman JN， Arbogast Patrick G，et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM[J]. Heart Rhythm， 2004，1：669-675.
     [13]Yusuf S， Sleight P， Pogue J， et al. Effects of an angiotensin-converting-enzyme inhibitor， ramipril， on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators[J]. N Engl J Med， 2000，342：145-153.
     [14]Pitt B， Zannad F， Remme WJ， et al. Randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J]. N Engl J Med， 1999，341：709-717.
     [15]Crabos M， Roth M， Hahn AW， et al. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression[J]. J Clin Invest， 1994，93：2372-2378.
     [16]Chen XQ， Dai QY. Statins in the treatment of atrial fibrillation[J]. J World Clinical Drugs， 2018， 39：584-587.
     [17]Oudot A， Vergely C， Ecarnot-Laubriet A， et al. Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion[J]. Eur J Pharmacol， 2003，462：145-154.
     [18]Nakagami H， Takemoto M， Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy[J]. J Mol Cell Cardiol， 2003，35：851-859.
     [19]Wu S， Gao J， Ohlemeyer C， et al. Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes[J]. Free Radic Biol Med， 2005，39：1601-1610.
     [20]Iravanian S， Dudley SC Jr. The renin-angioten-aldosterone system and cardiac arrhythmias[J]. Heart Rhythm， 2008， 5(6 Suppl)： S12 - S17.
     [21]Kobayashi N， Fukushima H， Takeshima H， et al. Effect of epleronone on endothelial progenitor cells and oxidative stress in ischemic hindlimb[J]. Am J Hypertens， 2010， 23(9)：1007-1013.
     [22]Ceron CS， Castro MM， Rizzi E， et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension[J]. Br J Pharmacol， 2010，160(1)：77-78.
     [23]Wang X， Desai K， Juurlink BH， et al. Gender-related differences in advanced glycation end products， oxidative stress markers and nitric oxide synthases in rats[J]. Kidney Int， 2006，69：281-287.
     [24]Ostgren CJ， Merlo J， Rastam L， et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community[J]. Diabetes Obes Metab， 2004，6：367-374.
     [25]Carnes CA， Chung MK， Nakayama T， et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation[J]. Circ Res， 2001，89：E32-E38.
     [26]Kim YM， Guzik TJ， Zhang YH， et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation[J]. Circ Res， 2005，97：629-636.
     [27]Dudley SC Jr， Hoch NE， McCann LA， et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage： Role of the NADPH and xanthine oxidases[J]. Circulation， 2005，112：1266-1273.
     [28]Tsai CT， Lai LP， Kuo KT， et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts： implication for the therapeutic effect of statin in atrial structural remodeling[J]. Circulation， 2008， 117(3)：344-355.
     [29]Yagi S， Akaike M， Aihara K， et al. Endothelial nitric oxide synthase-independent protective action against angiotensin II-induced atrial remodeling via reduced oxidant injury[J]. Hypertension， 2010，55(4)：918-923.
     [30]Yang D， Yuan J， Liu J， et al. Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B Axis[J]. Int J Med Sci， 2013，10(7)：812-824.
     [31]Butz S， Driamov S， Remondino A， et al. Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia[J]. J Pharm Pharmacol， 2004；，56：521-528.
     [32]Caouette D， Dongmo C， Berube J， et al. Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line[J]. Naunyn Schmiedebergs Arch Pharmacol， 2003，368：479-486.
     [33]Shang LL， Sanyal S， Pfahnl AE， et al. NF-κB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 2008；294：C372-92007.
     [34]Li SY， Yang X， Ceylan-Isik AF， et al. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation， oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch[J]. Diabetologia， 2006，49：1434-1446.
     [35]Benitah JP， Perrier E， Gomez AM， et al. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes[J]. J Physiol， 2001，537：151-160.
     [36]Shan J， Xie W， Betzenhauser M， et al. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia[J]. Circ Res， 2012， 111(6)：708-717.
     [37]Li N， Wang T， et al. Inhibition of CaMK II phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP 12.6 knockout mice[J]. Cir Res， 2012， 110(3)：465-470.
     [38]李雪. 急性心肌梗死后缺血再灌注性心律失常发病机制及预防的研究[J]. 世界最新医学信息文摘，2019，19(83)；114-115.
     [39]Lerner DL，Beardslee MA，Saffitz JE.The role of altered intercellular coupling in arrhythmias induced by acute myocardial ischemia[J]. Cardiovasc Res，2011，50（2）：263-269.
     [40]Beardslee MA，Lerner DL，Tadros PN，et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia[J]. Circ Res，2000，87 （8）：656-662.
     [41]Gutstein DE，Morley GE，Tamaddon H，et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43[J].Circ Res，2015，88（3）：333-339.
     [42]Aon MA，Cortassa S，MARBsan E，et al. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a localrelease of reactive oxygen species in cardiac myocytes[J]. J Biol Chem，2016，278（45）：44735-44744.
     [43]Kasi VS， Xiao HD， Shang LL， et al. Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation[J]. Am J Physiol Heart Circ Physiol， 2007，293：H182-H192.
     [44]Fischer R， Dechend R， Gapelyuk A， et al. Angiotensin II-induced sudden arrhythmic death and electrical remodeling[J]. Am J Physiol Heart Circ Physiol， 2007，293：H1242-H1253.
     [45]Axelsen LN， Haugan K， Stahlhut M， et al. Increasing gap junctional coupling： A tool for dissecting the role of gap junctions[J]. J Membr Biol， 2007，216：23-35.
     [46]Chaugai S， Meng WY， Ali Sepehry A. Effects of RAAS blockers on atrial fibrillation prophylaxis： an updated systematic review and meta-analysis of randomized controlled trials[J]. J Cardiovasc Pharmacol Ther， 2016， 21(4)： 388-404.
     [47]Bonnemeier H，Schfer U，Ortak J，et al. Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction[J]. Pacing Clin Electrophysiol，2007，30 Suppl 1： S160-S165.
     [48]Askari AT，Shishehbor MH，Kaminski MA，et al. The association between early ventricular arrhythmias，renin-angiotensin-aldosterone system antagonism，and mortality in patients with ST-segment-elevation myocardial infarction： Insights from global use of strategies to open coronary arteries (GUSTO) V [J]. Am Heart，2009，158(2)：238-243.

快速检索引用检索图表检索高级检索